New Biomarkers for Heart Failure with Normal Ejection Fraction
Author Information
Author(s): Dinh Wilfried, Nickl Werner, Füth Reiner, Lankisch Mark, Hess Georg, Zdunek Dietmar, Scheffold Thomas, Barroso Michael Coll, Tiroch Klaus, Ziegler Dan, Seyfarth Melchior
Primary Institution: Witten/Herdecke University, HELIOS Klinikum Wuppertal, Germany
Hypothesis
Are hsTnT and hFABP plasma levels elevated in patients with heart failure with normal ejection fraction?
Conclusion
In patients with heart failure and normal ejection fraction, hsTnT and hFABP levels are elevated, indicating ongoing myocardial damage.
Supporting Evidence
- hsTnT and hFABP levels were significantly higher in patients with asymptomatic LVDD and HFnEF compared to controls.
- hsTnT was detectable in 87% of HFnEF patients, indicating ongoing myocardial damage.
- hFABP levels were significantly different between normal diastolic function and asymptomatic LVDD groups.
Takeaway
This study found that two blood markers, hsTnT and hFABP, are higher in patients with a type of heart failure that usually has normal heart function, suggesting heart damage.
Methodology
The study analyzed hsTnT, hFABP, and NT-proBNP levels in 130 patients categorized into three groups: HFnEF, LVDD, and controls.
Potential Biases
The study's findings may be influenced by the high prevalence of CAD and other cardiovascular risk factors in the sample.
Limitations
The study had a small sample size and may not represent the general population due to high rates of CAD and cardiovascular risk factors.
Participant Demographics
Median age was 67 years, with 49% women; 62% had stable coronary artery disease.
Statistical Information
P-Value
p < 0.001
Confidence Interval
95% CI for hsTnT was 12.7-24.9 ng/L.
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website